# India

ADD (no change)

Consensus ratings*: Buy 13 H	Hold 2	Sell 1
Current price:		Rs122
Target price:		Rs141
Previous target:		Rs141
Up/downside:		15.6%
InCred Research / Consensus:		-5.9%
Reuters:		
Bloomberg:	ORC	MNT IN
Market cap:	US	S\$344m
	Rs2	4,984m
Average daily turnover:	U	S\$1.6m
	Rs	113.7m
Current shares o/s:		204.9m
Free float: *Source: Bloomberg		58.9%

## Key changes in this note

- > Net sales raised by 0%-1% for FY23F-25F.
- EBITDA cut by 2%-4% for FY23F-25F.
- Rollover target price to Dec 2024F.



Major shareholders	% neid
Promoter & Promoter Group	37.9
Nippon Life India	2.4
Franklin India	2.4

# **Orient Cement**

# A strong comeback 3Q; all-round beat

- 3QFY23 EBITDA stood at Rs903m, 54% above our estimate (down 23% yoy while up 178% qoq), on higher-than-expected sales/realization and lower cost.
- We cut our FY24F-24F EBITDA estimates by ~2%-3% to factor in the lower pricing growth. Delay in expansion projects could restrict growth in the near term.
- We retain ADD rating on the stock with an unchanged target price of Rs141.

### Volume/realization above expectations; demand to remain robust

Cement sales volume of Orient Cement (ORCMNT) in 3QFY23 rose by 17.4% yoy and 16% qoq to 1.43mt, 6% above our estimate, on higher B2B sales (51%) in its key states. Capacity utilization improved to 70% which resulted in a higher volume. Cement realization stood at Rs5,121/t (up 1% yoy and 3% qoq). However, the pricing has been a concern. There was no hike in cement prices to offset higher cost. ORCMNT is awaiting regulatory nod for capacity expansion at its 2mtpa split grinding unit at Tiroda in Maharashtra, which was earlier targeted for commissioning by FY25F and plans to proceed with a 2mtpa clinker expansion at Devapur unit only after visibility on the grinding unit. Thereafter, in the second phase of expansion, it will put up a plant in Rajasthan which will take another three-to-four years because of pending land acquisition. We factor in a 5.8% volume CAGR over FY22-25F, as new capacity will be ramped up post FY25F and there's limited visibility on capacity expansion in the near term.

### Unit EBITDA improves on lower cost; margins to improve further

Total cost/t was up 9% yoy while down 5% qoq at Rs4,489 because of lower raw material, fuel, packaging and fixed cost where a) power and fuel cost/t was up only 1% qoq while it was still up 38% yoy at Rs1,590 mainly on account of a steep hike in fuel price which was partially mitigated by improved efficiency and savings accrued from solar power plant, b) freight cost/t inched up by ~6% yoy and 4% qoq to Rs1,373 mainly on account of higher road volume and general inflationary trend (average lead distance remained higher during the quarter from average of 300kms) and c) raw material cost/t was down by 5% yoy and 24% qoq to Rs661 during the quarter. All this led to an EBITDA/t improvement of 140% qoq (down 35% yoy) to Rs633. Pet-coke and coal prices have come down, but the company has high-cost inventory and costs will remain higher in 4QFY23F as well. Cost reduction will only be seen from Jun 2023F. We expect lower cost and higher volume (as demand remains strong) going ahead to help margin recovery in FY24F. ORCMNT's 10MW WHRS is on track to be commissioned by FY23F-end; it will improve the margin from FY24F onwards. We thus factor in Rs890/950 EBITDA/t growth in FY24F/25F, respectively.

## Maintain ADD rating; valuation attractive

At the CMP of Rs123, ORCMNT trades at FY24F/25F EV/EBITDA of 6.6x/6.7x, respectively. We retain ADD rating on it. Our target price of Rs141 (unchanged) is based on 6.5x (unchanged) EV/EBITDA and rollover to Dec 2024F. Weak demand, pricing pressure, delay in expansion, and a rise in input cost are key downside risks.

Financial Summary	Mar-21A	Mar-22A	Mar-23F	Mar-24F	Mar-25F
Revenue (Rsm)	23,241	27,254	28,774	31,625	33,791
Operating EBITDA (Rsm)	5,507	5,911	3,555	5,465	6,161
Net Profit (Rsm)	2,142	2,633	1,155	2,352	2,674
Core EPS (Rs)	10.5	12.8	5.6	11.5	13.1
Core EPS Growth	147.4%	22.9%	(56.1%)	103.6%	13.7%
FD Core P/E (x)	11.66	9.49	21.63	10.62	9.34
DPS (Rs)	1.5	2.5	0.6	1.1	1.3
Dividend Yield	1.23%	2.05%	0.92%	1.88%	2.14%
EV/EBITDA (x)	5.71	4.66	8.16	6.48	6.65
P/FCFE (x)	20.96	24.82	(30.59)	71.56	(11.19)
Net Gearing	49.4%	16.8%	25.0%	57.6%	79.3%
P/BV (x)	1.91	1.64	1.54	1.38	1.24
ROE	17.7%	18.6%	7.3%	13.7%	14.0%
% Change In Core EPS Estimates			(0.56%)	(0.39%)	(0.37%)
InCred Research/Consensus EPS (x)					

Analyst(s)



Nishant BAGRECHA T (91) 22 4161 1564 E nishant.bagrecha@incredcapital.com

SOURCE: INCRED RESEARCH, COMPANY REPORTS

# A strong comeback 3Q; all-round beat

Particulars (Rs m)	3QFY23	3QFY23F	2QFY23	3QFY22 —		% Change	
					3QFY23F	2QFY23	3QFY22
Net Sales	7,323	6,813	6,153	6,175	7%	19%	19%
Raw materials consumed	946	1,109	1,071	849	-15%	-12%	11%
Freight and forwarding expenses	1,963	1,791	1,638	1,585	10%	20%	24%
Power and fuel cost	2,274	2,034	1,937	1,399	12%	17%	63%
Employee cost	426	466	433	416	-9%	-2%	2%
Other expenses	811	826	749	751	-2%	8%	8%
Total expenditure	6,419	6,227	5,827	5,000	3%	10%	28%
EBITDA	903	586	326	1,175	54%	178%	-23%
Depreciation	371	372	369	368	0%	0%	1%
EBIT	533	214	-44	807	149%	1319%	-34%
Interest	97	106	105	158	-8%	-8%	-38%
Other income	11	30	48	25	-62%	-77%	-54%
РВТ	447	138	-101	674	224%	543%	-34%
Tax	171	49	-6	237	247%	3013%	-28%
PAT before MI & associate cos.	275	88	-95	437	211%	390%	-37%
Minority interest	0	0	0	0			
Profit from associate cos.	0	0	0	0			
Recurring PAT	275	88	-95	437	211%	390%	-37%
Extraordinary items	0	0	0	0			
Reported PAT	275	88	-95	437	211%	390%	-37%
EPS (Rs)	1.3	0.4	-0.5	2.1	211%	390%	-37%
Gross margin	29%	28%	24%	38%	166 bp	474 bp	-870 bp
EBITDA margin	12.3%	8.6%	5.3%	19.0%	374 bp	705 bp	-670 bp
EBIT margin	7%	3%	-1%	13%	414 bp	798 bp	-580 bp
PBT margin	6%	2%	-2%	11%	408 bp	774 bp	-481 bp
PAT margin	4%	1%	-2%	7%	246 bp	530 bp	-331 br
Tax rate	38%	36%	6%	35%	255 bp	3,252 bp	316 bp
Cost items as % of sales							
Raw material cost	13%	16%	17%	14%	-337 bp	-450 bp	-84 br
Freight cost	27%	26%	27%	26%	52 bp	19 bp	114 b
P&F cost	31%	30%	31%	23%	119 bp	-43 bp	840 br

Den terme en else la	2057/02	2057025		205700	% Change		
Per tonne analysis	3QFY23	3QFY23F	2QFY23	3QFY22 —	3QFY23F	2QFY23	3QFY22
Sales volume (cement + clinker)	1.43	1.35	1.24	1.22	6%	16%	17.4%
Realization	5,121	5,028	4,978	5,070	2%	3%	1%
EBITDA/t	632	432	263	965	46%	140%	-35%
RM cost/t	661	819	867	697	-19%	-24%	-5%
P&F cost/t	1,590	1,501	1,567	1,149	6%	1%	38%
Freight cost/t	1,373	1,322	1,325	1,301	4%	4%	6%
Employee cost/t	298	344	350	341	-13%	-15%	-13%
Other expenses/t	567	610	606	617	-7%	-6%	-8%
Cost/t	4,489	4,596	4,715	4,105	-2%	-5%	9%






Figure 3: Cement sales volume improved by 17% yoy and 16%


# Key quarterly charts ➤

Figure 4: Cement realization increased by 1% yoy while it was up 3% qoq in 3QFY23









Rs.m	New			Old			Change (%)		
	FY23F	FY24F	FY25F	FY23F	FY24F	FY25F	FY23F	FY24F	FY25F
Sales	28,774	31,625	33,791	28,605	31,304	33,647	1%	1%	0%
EBITDA	3,555	5,465	6,161	3,701	5,557	6,364	-4%	-2%	-3%
PAT	1,155	2,352	2,674	1,233	2,396	2,783	-7%	-2%	-4%
EPS (Rs.)	5.6	11.5	13.1	6	12	14	-7%	-2%	-4%

Figure 8: Change in our estimates vs. Bloomberg consensus estimates										
Rs. m	Inc	red	Consensus				Chang	ge (%)		
	FY23F	FY24F	FY25F	FY23F	FY24F	FY25F	FY23F	FY24F	FY25F	
Sales	28,774	31,625	33,791	28,750	31,951	34,280	0%	-1%	-1%	
EBITDA	3,555	5,465	6,161	3,768	5,605	6,129	-6%	-3%	1%	
PAT	1,155	2,352	2,674	1,322	2,448	2,378	-13%	-4%	12%	
	SOURCE: INCRED RESEARCH ESTIMATES, COMPANY REPORTS, BLOOMBERG									

# **InCred** Equities


Cement   India	
Orient Cement	February 03, 2023

1	Elaura	٥.	Kow		ntiono
	Figure	9:	ĸey	assum	ptions

Figure 9. Key assumptions					
	FY21A	FY22A	FY23A	FY24F	FY25F
Volume (in mtpa)	5.0	5.5	5.6	6.1	6.5
уоу	-13%	9%	3%	9%	6%
Realization (per tonne)	4,604	4,975	5,100	5,166	5,207
уоу	10%	8%	2%	1%	1%
Cost (per tonne)	3,513	3,896	4,469	4,273	4,258
уоу	0%	11%	15%	-4%	0%
EBITDA (per tonne)	1,091	1,079	630	893	949
уоу	65%	-1%	-42%	42%	6%
EBITDA (Rs m)	5,507	5,911	3,555	5,465	6,161
уоу	44%	7%	-40%	54%	13%
	SOU	RCE: INCRED RE	SEARCH ESTIM	ATES, COMPANY	' REPORTS


# Figure 10: Our target price of Rs141 is based on 6.5x Dec 2024F EV/EBITDA Valuation TP Target EV/EBITDA (x) 6.5 Target EV/EBITDA (x) 40.000

Target EV (Rs m)	40,229
Net debt / (cash) (Rs m)	10,404
No. of shares (m)	205
Fair value per share (Rs)	141
	SOURCE: INCRED RESEARCH ESTIMATES, COMPANY REPORTS



# **InCred** Equities

## **BY THE NUMBERS**



## Profit & Loss

(Rs mn)	Mar-21A	Mar-22A	Mar-23F	Mar-24F	Mar-25F
Total Net Revenues	23,241	27,254	28,774	31,625	33,791
Gross Profit	23,241	27,254	28,774	31,625	33,791
Operating EBITDA	5,507	5,911	3,555	5,465	6,161
Depreciation And Amortisation	(1,419)	(1,452)	(1,481)	(1,526)	(1,571)
Operating EBIT	4,088	4,459	2,074	3,939	4,589
Financial Income/(Expense)	(936)	(514)	(381)	(392)	(549)
Pretax Income/(Loss) from Assoc.					
Non-Operating Income/(Expense)	183	96	105	116	125
Profit Before Tax (pre-El)	3,336	4,040	1,799	3,663	4,165
Exceptional Items					
Pre-tax Profit	3,336	4,040	1,799	3,663	4,165
Taxation	(1,194)	(1,407)	(644)	(1,311)	(1,491)
Exceptional Income - post-tax					
Profit After Tax	2,142	2,633	1,155	2,352	2,674
Minority Interests					
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	2,142	2,633	1,155	2,352	2,674
Recurring Net Profit	2,142	2,633	1,155	2,352	2,674
Fully Diluted Recurring Net Profit	2,142	2,633	1,155	2,352	2,674

Cash Flow					
(Rs mn)	Mar-21A	Mar-22A	Mar-23F	Mar-24F	Mar-25F
EBITDA	5,507	5,911	3,555	5,465	6,161
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(1,939)	51	(1,691)	634	(616)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense	183	96	105	116	125
Other Operating Cashflow	3,734	(962)	(962)	(962)	(962)
Net Interest (Paid)/Received	(936)	(514)	(381)	(392)	(549)
Tax Paid	590	658	(644)	(1,311)	(1,491)
Cashflow From Operations	7,141	5,239	(17)	3,549	2,668
Сарех	(507)	(525)	(2,200)	(9,700)	(7,700)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments					
Other Investing Cashflow	(1,109)	1,227	(300)	(1,200)	(1,500)
Cash Flow From Investing	(1,615)	702	(2,500)	(10,900)	(9,200)
Debt Raised/(repaid)	(4,333)	(4,935)	1,700	7,700	4,300
Proceeds From Issue Of Shares					
Shares Repurchased					
Dividends Paid	(307)	(512)	(115)	(235)	(267)
Preferred Dividends					
Other Financing Cashflow	(881)	(414)	1,146	1,227	1,194
Cash Flow From Financing	(5,521)	(5,861)	2,731	8,692	5,227
Total Cash Generated	4	80	214	1,341	(1,305)
Free Cashflow To Equity	1,192	1,007	(817)	349	(2,232)
Free Cashflow To Firm	6,461	6,455	(2,136)	(6,959)	(5,984)

SOURCE: INCRED RESEARCH, COMPANY REPORTS

# BY THE NUMBERS...cont'd

(Rs mn)	Mar-21A	Mar-22A	Mar-23F	Mar-24F	Mar-25F
Total Cash And Equivalents	1,512	538	752	2,093	787
Total Debtors	1,012	1.273	1.734	1.906	2.037
Inventories	1,705	1,866	2,365	2,599	2,007
Total Other Current Assets	535	652	921	949	1,149
Total Current Assets	4,854	4,329	5,772	7,547	6,750
Fixed Assets	22,073	21,151	21,670	29,645	35,573
Total Investments	22,010	42	42	42	42
Intangible Assets	413	398	698	1.898	3,398
Total Other Non-Current Assets	781	576	776	976	1,176
Total Non-current Assets	23,266	22,167	23,185	32,560	40,188
Short-term Debt	,	1.617	3.717	4.917	5,717
Current Portion of Long-Term Debt		.,	0,7 11	.,	0,111
Total Creditors	1,844	2,310	2,059	2.396	2.399
Other Current Liabilities	2,868	2,801	2,590	3,321	3,210
Total Current Liabilities	4,712	6,727	8,365	10,633	11,326
Total Long-term Debt	7,966	1,480	1,080	7,580	11,080
Hybrid Debt - Debt Component	.,	.,	.,	.,	.,
Total Other Non-Current Liabilities	2,383	3,034	3,334	3,834	4,334
Total Non-current Liabilities	10,349	4,514	4.414	11,414	15,414
Total Provisions	-,	7-	,	,	- /
Total Liabilities	15,062	11,242	12,779	22,048	26,740
Shareholders Equity	13,059	15,254	16,178	18,059	20,199
Minority Interests	,		,	,	
Total Equity	13,059	15,254	16,178	18,059	20,199
Key Ratios					
	Mar-21A	Mar-22A	Mar-23F	Mar-24F	Mar-25F
Revenue Growth	(4.0%)	17.3%	5.6%	9.9%	6.8%
Operating EBITDA Growth	43.8%	7.3%	(39.8%)	53.7%	12.7%
Operating EBITDA Margin	23.7%	21.7%	12.4%	17.3%	18.2%
Net Cash Per Share (Rs)	(31.50)	(12.49)	(19.74)	(50.78)	(78.14)
BVPS (Rs)	63.74	74.46	78.97	88.15	98.59
Gross Interest Cover	4.37	8.67	5.45	10.05	8.36
Effective Tax Rate	35.8%	34.8%	35.8%	35.8%	35.8%
Net Dividend Payout Ratio	14.3%	19.5%	20.0%	20.0%	20.0%
Accounts Receivables Days	21.36	15.90	19.08	21.01	21.29
Inventory Days	31.97	23.92	26.84	28.65	29.04
Accounts Payables Days	37.13	35.52	31.61	31.08	31.67
ROIC (%)	18.7%	21.4%	8.8%	12.2%	11.3%
ROCE (%)	18.4%	22.6%	10.5%	15.3%	13.6%
Return On Average Assets	10.8%	11.5%	5.5%	7.9%	7.4%

SOURCE: INCRED RESEARCH, COMPANY REPORTS

### DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd.(formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000007793. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other nonconfidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

# **InCred** Equities

#### Cement | India Orient Cement | February 03, 2023

	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from the subject company in the last twelve months		NO
nanaged or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report		NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

## Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in thisreport and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.